GDANSK/LONDON, March 28 (Reuters) - Bank of America analysts on Friday said Novo Nordisk (NOVOb.CO), opens new tab may miss first-quarter expectations, as sales of its blockbuster Wegovy and ...
Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...
Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity and related metabolic disorders.
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
The high-profile Danish pharmaceutical company got a price-target cut from an analyst. That pundit remains lukewarm at best on the Wegovy maker's prospects. Well before market open that morning ...
March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...
Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest monthly loss since July 2002. Investors are worried that the company is ...
The new PenCycle programme covers Novo Nordisk's FlexPen and FlexTouch devices, which are used to dispense insulin and other medications.
Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has soared some 40 per cent over the last year as investors celebrated its ...
Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...